Insulin sensitivity enhancement (null)

"Insulin sensitivity enhancement" refers to the improvement in the ability of peripheral tissues such as muscle, adipose tissue, and liver to respond to circulating insulin. This process is a key therapeutic goal in managing conditions like type 2 diabetes and metabolic syndrome, where insulin resistance is central to disease pathogenesis[6][7]. Insulin sensitivity enhancement can be achieved pharmacologically by modulating several molecular pathways involved in insulin signaling, glucose uptake, lipid metabolism, and inflammation. Rather than being a single molecular target, enhancement of insulin sensitivity is the result of complex cellular and molecular interactions, which is why drugs acting on diverse proteins, such as AMPK, PPARγ, and insulin receptors, may produce this effect[1][2][4][6][7]. As such, it cannot be classified as a target molecule, receptor, or enzyme, but rather as a physiological or therapeutic consequence of targeted interventions. Important caveat: Since "insulin sensitivity enhancement" is not a molecule, gene, receptor, or protein, but a pharmacological/therapeutic effect, it should not be used as a canonical target name in structured target-molecule or drug databases. To retrieve druggable targets, focus on specific proteins or receptors such as "Peroxisome proliferator-activated receptor gamma (PPARγ)" or "Insulin receptor."[2][6][7]

Other names

increased insulin sensitivityinsulin sensitizationimproved insulin responsiveness

Improving sensitivity of insulin receptor signaling (e.g., via IRS/PI3K/Akt pathway); Increasing glucose uptake in skeletal muscle via GLUT4 translocation; Reducing hepatic gluconeogenesis; Reducing inflammatory mediators and oxidative stress; Activating AMP-activated protein kinase (AMPK) pathway (e.g., metformin, berberine); Modulating adipokine and cytokine signaling (e.g., via PPARγ)